Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded at Zacks Research

Zacks Research upgraded shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a hold rating to a strong-buy rating in a report published on Monday,Zacks.com reports.

MIST has been the topic of several other research reports. TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Wells Fargo & Company increased their target price on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $8.00.

Milestone Pharmaceuticals Trading Down 3.5%

Milestone Pharmaceuticals stock opened at $1.94 on Monday. Milestone Pharmaceuticals has a 52 week low of $0.63 and a 52 week high of $3.06. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. The firm has a market capitalization of $165.23 million, a price-to-earnings ratio of -2.37 and a beta of 0.44. The company has a 50 day moving average price of $2.23 and a 200 day moving average price of $1.96.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. Research analysts forecast that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Insider Activity

In other Milestone Pharmaceuticals news, COO Jeffrey Edward Nelson sold 58,007 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $134,576.24. Following the completion of the transaction, the chief operating officer owned 41,993 shares of the company’s stock, valued at $97,423.76. The trade was a 58.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Lorenz Muller sold 53,566 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $2.32, for a total value of $124,273.12. Following the completion of the sale, the insider directly owned 196,486 shares in the company, valued at approximately $455,847.52. This represents a 21.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 416,327 shares of company stock worth $935,458 in the last 90 days. Insiders own 19.50% of the company’s stock.

Institutional Trading of Milestone Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MIST. Sapient Capital LLC bought a new position in Milestone Pharmaceuticals in the 3rd quarter worth approximately $25,000. Bank of America Corp DE grew its stake in shares of Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after acquiring an additional 16,044 shares during the last quarter. Stephenson & Company Inc. bought a new position in Milestone Pharmaceuticals during the third quarter worth $40,000. Creative Planning raised its stake in Milestone Pharmaceuticals by 74.6% during the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Bay Rivers Group raised its stake in Milestone Pharmaceuticals by 72.9% during the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock valued at $58,000 after purchasing an additional 12,170 shares during the last quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

Key Stories Impacting Milestone Pharmaceuticals

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
• Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from “Hold” to a “Strong Buy” (Zacks Rank #1), which may attract buyers and short‑term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
• Neutral Sentiment: Trading context: shares are trading below the 50‑day moving average and volume is below the stock’s average, which can mute a sustained bounce despite the product launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 – Joseph Oliveto
• Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 – David Bharucha SEC Form 4 – Lorenz Muller
• Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 – Jeffrey Edward Nelson

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.